Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.

Respiratory investigation - 1 Nov 2016

Wada Yosuke, Koyama Shigeru, Kuraishi Hiroshi, Miyahara Takashige, Yoshiike Fumiaki, Agatsuma Toshihiko, Yamamoto Ryouhei, Ono Yasushi, Suzuki Toshiro, Hachiya Tsutomu, Gomi Daisuke, Tateishi Kazunari, Hanaoka Masayuki, Koizumi Tomonobu

Abstract excerpt

BACKGROUND: Afatinib has been available in Japan for the treatment of epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) since May 2014. We conducted an observational study in patients treated with afatinib in Nagano prefecture, focusing on response and associated toxicities. METHODS: We analyzed the clinical records of NSCLC patients treated with afatinib between May 2014 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Afatinib
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to Feasibility Studies

Share to Neoplasm Staging

Share to Quinazolines

Share to Radiation-Sensitizing Agents

Source

Identifiers

PMID: 27886858
DOI: 10.1016/j.resinv.2016.07.003

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical analysis of patients treated with afatinib for advanced non-small cell lung cancer: A Nagano Lung Cancer Research Group observational study.PMID 27886858Read ↗

A prospective, phase II trial of monotherapy with low-dose afatinib for patients with EGFR, mutation-positive, non-small cell lung cancer: Thoracic oncology research group 1632.Semantic proximity Read ↗

The safety of afatinib for the treatment of non-small cell lung cancer.Semantic proximity Read ↗

Effectiveness and safety of afatinib, gefitinib, and erlotinib for treatment-naïve elderly patients with epidermal growth factor receptor-mutated advanced non-small-cell lung cancer: a multi-institute retrospective study.Semantic proximity Read ↗

A phase II study of first-line afatinib for patients aged ≥75 years with EGFR mutation-positive advanced non-small cell lung cancer: North East Japan Study Group Trial NEJ027Semantic proximity Read ↗

An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations.Semantic proximity Read ↗

Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer.Semantic proximity Read ↗

Afatinib: A first-line treatment for selected patients with metastatic non-small-cell lung cancer.Semantic proximity Read ↗

Phase II Study of Low-Dose Afatinib Maintenance Treatment Among Patients with EGFR-Mutated Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1601 (NJLCG1601).Semantic proximity Read ↗

Application of afatinib combined with np regimen in the treatment of stage iv non-small cell lung cancer and its effect on patient survival.Semantic proximity Read ↗

Neoadjuvant Afatinib for stage III EGFR-mutant non-small cell lung cancer: a phase II study.Semantic proximity Read ↗

Survival of chemo-naïve patients with EGFR mutation-positive advanced non-small cell lung cancer after treatment with afatinib and bevacizumab: updates from the Okayama Lung Cancer Study Group Trial 1404.Semantic proximity Read ↗

A phase I trial of afatinib and bevacizumab in chemo-naïve patients with advanced non-small-cell lung cancer harboring EGFR mutations: Okayama Lung Cancer Study Group Trial 1404.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.